Literature DB >> 11710686

Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.

S Sahoo1, S A Hoda, J Rosai, R A DeLellis.   

Abstract

To evaluate the expression of cytokeratin (CK) 19, we stained sections obtained from formalin-fixed, paraffin tissue blocks of 35 thyroid tumors (follicular adenoma [FA], 20; papillary thyroid carcinoma [PTC], 10 follicular variant [FV] and 5 usual type) and scored the extent of staining as follows: 1+ (<5% positively stained cells), 2+ (5%-25% positively stained cells), 3+ (25%-75% positively stained cells), and 4+ (>75% positively stained cells). All 15 PTCs (including 10 FV-PTCs) were CK19 positive: 14 were 4+ and 1 (FV-PTC) was 2+. All 20 FAs also were CK19 positive: 15 were 1+, 1 was 2+, 4 were 3+, and none was 4+. In the FAs that were scored 1+, reactivity usually was confined to follicular cells lining cystically dilated atrophic follicles that lacked the typical nuclear features of PTC. The remaining FAs showed more diffuse reactivity, which was, however, less intense than that observed in the PTCs. Thus, immunoreactivity for CK19 is not specific for PTC, although we acknowledge that the extent and intensity of staining are considerably greater in this tumor than in FA. There were no significant differences in staining for CK19 between nonneoplastic follicles adjacent to PTCs and those adjacent to FAs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11710686     DOI: 10.1309/6D9D-7JCM-X4T5-NNJY

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  33 in total

Review 1.  The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia.

Authors:  Simon J Raphael
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

2.  Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis.

Authors:  Jennifer L Hunt; Zubair W Baloch; Leon Barnes; Patricia A Swalsky; Cindy L Trusky; E Sesatomi; Sydney Finkelstein; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 3.  Best practice in thyroid pathology.

Authors:  C E Anderson; K M McLaren
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

4.  Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland.

Authors:  Valeria Barresi; Enrica Vitarelli; Luca Reggiani Bonetti; Giovanni Tuccari; Gaetano Barresi
Journal:  Virchows Arch       Date:  2012-02-28       Impact factor: 4.064

Review 5.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

6.  Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases.

Authors:  Lester D R Thompson; Jacqueline A Wieneke; Clara S Heffess
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

7.  Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions.

Authors:  Hanan AlSaeid Alshenawy
Journal:  Pathol Oncol Res       Date:  2014-03-23       Impact factor: 3.201

8.  The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions.

Authors:  E Raggio; M Camandona; D Solerio; P Martino; A Franchello; F Orlandi; G Gasparri
Journal:  J Endocrinol Invest       Date:  2009-07-21       Impact factor: 4.256

Review 9.  Newer developments in immunohistology.

Authors:  A S-Y Leong; T Y-M Leong
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

10.  Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.

Authors:  Magdalena Slosar; Poonam Vohra; Manju Prasad; Andrew Fischer; Robert Quinlan; Ashraf Khan
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.